Medilink Therapeutics (suzhou) Co., Ltd.

This study tests a new drug, YL201, in people with advanced solid tumors that have not responded to other treatments. The trial has two parts: first, finding a safe dose, and second, testing how well it works in specific cancer types. About 312 adults will take part in China and …

This study tests a new drug, YL205, in 252 adults with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. It is an early-phase trial, so the focus is on safety and dosing, not a…

This early-phase study tests a new drug, YL211, in about 155 adults with advanced solid tumors that have not responded to standard treatments. The study has three parts to find the safest dose and check for side effects, while also looking at whether the drug can shrink tumors. P…

This study tests a new drug, YL242, alone or with other treatments, in people with advanced solid tumors that have not responded to prior therapy. The goal is to check safety, how the drug moves through the body, and whether it shrinks tumors. About 424 adults will take part acro…

This study tests an experimental drug called YL202 in about 200 people with advanced solid tumors, including lung, breast, and head & neck cancers. The goal is to see if the drug can shrink tumors and how safe it is. Participants must be between 18 and 75 years old and have tried…

This study tests a new drug (YL201) combined with an immunotherapy (toripalimab), with or without chemotherapy (cisplatin), in people whose nasopharyngeal cancer has come back or spread. The goal is to see if the combination is safe and helps control the cancer. About 202 adults …

This study tests an experimental drug called YL202 in about 100 adults with advanced solid tumors, including lung, colorectal, and cervical cancers that have not responded to other treatments. The main goal is to see if YL202 can shrink tumors. Participants will receive the drug …

This study tests a new drug called YL202 combined with other cancer treatments in people with advanced solid tumors, including breast and lung cancer. The goal is to find a safe dose and see if the combination can shrink tumors. About 414 adults aged 18-75 who have already tried …

This study tests a new drug called YL201 combined with atezolizumab in people with advanced small cell lung cancer. The goal is to find the safest and most effective dose. About 118 adults who have not had prior treatment for this cancer will take part. The treatment continues un…

This study is testing a new drug combination (YL201 and ivonescimab) in people with advanced solid tumors, including certain lung cancers. The goal is to see if the combination is safe and can shrink tumors. About 260 adults will take part, and the study is currently recruiting.

This early-phase study tests a new drug, YL217, in about 220 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects, while also seeing if the drug can shrink tumors. Participants must be …